Clinical trial

D-dimer Prognostic Marker of Cerebral Infarction After Revascularization Procedure

Name
PI2020_843_0159
Description
Cerebral infarction is the leading cause of acquired disability in adults. Absence of biological marker used in current practice and identified as a prognostic factor for recovery. D-dimers are degradation products of stabilized fibrin translating an activation of coagulation whatever the cause. Studies have shown that increased D-dimer levels in patients with MI is associated with a higher mortality rate, the link with post-intervention non-revascularization has been demonstrate. The purpose of this project is to search for a correlation between the level of D-dimer and the degree of recovery evaluated by the NIHSS score
Trial arms
Trial start
2021-06-15
Estimated PCD
2023-09-01
Trial end
2023-09-01
Status
Recruiting
Treatment
blood sample
D-dimer measurement in blood sample
Size
60
Primary endpoint
Correlation between D-dimer concentration and NIHSS score
3 months
Correlation between D-dimer concentration and NIHSS score
6 months
Correlation between D-dimer concentration and the Rankin score
3 months
Correlation between D-dimer concentration and the Rankin score
6 months
Eligibility criteria
Inclusion Criteria: * Patients aged 18 to 65 * Cerebral infarctions undergoing a revascularization procedure by thrombolysis and / or thrombectomy, at the Amiens University Hospital between January 2015 and December 2020. * Patients having benefited from a D-dimer assay (during their stay) Exclusion Criteria: -
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'CASE_ONLY', 'timePerspective': 'RETROSPECTIVE'}, 'bioSpec': {'retention': 'SAMPLES_WITHOUT_DNA', 'description': 'D-Dimer measurement in blood sample'}, 'enrollmentInfo': {'count': 60, 'type': 'ESTIMATED'}}
Updated at
2023-05-10

1 organization

1 product

2 indications

Indication
Stroke